Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2136441 | 1.00 | HDAC1 (0.53) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL2606707 | 0.91 | HDAC1 (0.65) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL7942104 | 0.87 | HDAC2 (0.55) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL21480731 | 0.87 | HDAC2 (0.53) | HDAC1HDAC2HDAC3 | |
| SCHEMBL2685209 | 0.86 | HDAC1 (0.52) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL2464648 | 0.86 | HDAC2 (0.56) | HDAC1HDAC2HDAC3TP53LMNA | |
| SCHEMBL2133086 | 0.85 | HDAC1 (0.46) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL2133094 | 0.85 | HDAC1 (0.46) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL2131416 | 0.85 | HDAC1 (0.45) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL2131411 | 0.85 | HDAC1 (0.45) | HDAC1HDAC2HDAC3HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101147-A1 | INHIBITION OF HDAC2 TO PROMOTE MEMORY | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101147-A1 | INHIBITION OF HDAC2 TO PROMOTE MEMORY | HDAC2, HDAC1, HDAC3 | HDAC1 2/4885HDAC2 1/4885HDAC3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.